In a World Economic Forum talk, Professor Sumantra Ghosal - the founding Dean of the Indian School of Business, Hyderabad - talked about the "Smell of the Workplace" as a metaphor to describe the need for creating a new context that enables employees to change their mindset from that of Constraint, Compliance, Control and Contract to that of Stretch, Discipline, Trust and Support.

Sales Force Strategy in the Digital World

Does Your Company Have a Well Thought-out Strategy on...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Marketing

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Policies/Sales

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Strategy

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

The Pill is Now a Commodity – Can ‘Beyond the Pill’ Models Work in India?

The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered. The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model. Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison. ‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product. Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it. A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it. The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).